Thrombosis

New treatments show promise for management of blood clotting disorder

Published in Biotech Business Week, January 3rd, 2005

Two studies presented during the 46th Annual Meeting of the American Society of Hematology (ASH) highlight the effects of a promising new pipeline therapy for treatment of immune thrombocytopenic purpura (ITP).

ITP is a disorder that affects approximately 20,000 individuals in the United States and is characterized by an immune system malfunction that recognizes the body's own platelets as foreign and destroys them, potentially resulting in dangerously low platelet counts and the occurrence of spontaneous bleeding and bruising in the most severe cases.

Normal platelet range for a person without ITP is 150,000 - 400,000 platelets per microliter....

Want to see the full article?

Purchase this article for only $3.00

We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.

Welcome to NewsRx!

Learn more about a six-week, no-risk free trial of Biotech Business Week

Source: Biotech Business Week (2005-01-03)

NewsRx is Social

Top Medical Newsletters

Awards

Best Health/Healthcare Content, 2012
Best Health/Healthcare Content, 2011
Best e-Business Site, 2010
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005

Facts & Stats

NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.

Google 2010 PageRank: #2 Among Top Health News and Media Publications
Google 2010 PageRank: #2 Among Top Science Publications in Biology/Physiology
Google 2010 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
Amazon's Alexa 2010 PageRank: #2 News and Media Site for the Pharmaceutical Industry